Please try another search
For the three months ended 31 March 2022, Prestige Biologics Co Ltd revenues was not reported. Net loss increased from W1.59B to W11.4B. Higher net loss reflects R & D Expense - Balancing value increase from W2.08B to W8.18B (expense), Loss on Foreign Currency Translation decrease from W14M (income) to W1.33B (expense), Depreciation in R&D increase from W85.9M to W893.1M (expense).
Period Ending: | Sep 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
---|---|---|---|---|
Total Revenue | 914.5 | 53.56 | 1.52 | 14.05 |
Gross Profit | 808.26 | 5.62 | -4.06 | -1.5 |
Operating Income | -7903.47 | -12364.44 | -10371.25 | -7566.05 |
Net Income | -10446.2 | -9275.05 | -1798.98 | -19663 |
Period Ending: | Sep 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
---|---|---|---|---|
Total Assets | 310931.45 | 319050.18 | 258079.24 | 262652.47 |
Total Liabilities | 221557.37 | 210603.16 | 140467.88 | 143359.54 |
Total Equity | 89374.09 | 108447.01 | 117611.35 | 119292.93 |
Period Ending: | Sep 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 4164.5 | 454.01 | -7317.73 | -13062.81 |
Cash From Investing Activities | -5384.29 | -8541.88 | -5916.76 | -9086.84 |
Cash From Financing Activities | 2568.55 | 43289.22 | -309.83 | 2619.8 |
Net Change in Cash | 1349.03 | 35185.24 | -14462.47 | -19083.42 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review